[
  {
    "ts": null,
    "headline": "Biogen : to Participate in the Stifel 2025 Virtual CNS Forum",
    "summary": "Cambridge, MA, - - Biogen Inc. announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in a fireside chat during the Stifel 2025 Virtual CNS Forum. The webcast will be...",
    "url": "https://finnhub.io/api/news?id=29cb35fc3b571081085a2157fee9e4eae1a9ec147f388a13d39323234e3c1d6c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741711163,
      "headline": "Biogen : to Participate in the Stifel 2025 Virtual CNS Forum",
      "id": 133139357,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge, MA, - - Biogen Inc. announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in a fireside chat during the Stifel 2025 Virtual CNS Forum. The webcast will be...",
      "url": "https://finnhub.io/api/news?id=29cb35fc3b571081085a2157fee9e4eae1a9ec147f388a13d39323234e3c1d6c"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients",
    "summary": "Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1Felzartamab, with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen’s late-stage immunology portfolio CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced",
    "url": "https://finnhub.io/api/news?id=d65557b14f2672254399427444822260c1d808fe9b97c76cef4b5cf429234aa1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741692600,
      "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients",
      "id": 133191252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1Felzartamab, with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen’s late-stage immunology portfolio CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced",
      "url": "https://finnhub.io/api/news?id=d65557b14f2672254399427444822260c1d808fe9b97c76cef4b5cf429234aa1"
    }
  }
]